ArticleAmerican journal of translational research2026
Sodium hyaluronate/lysine nanoparticles loaded with si-VEGF-A inhibits corneal neovascularization.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study designed sodium hyaluronate/lysine (SH/Lys)-based nanoparticles loaded with vascular endothelial growth factor A (VEGF-A) siRNA (V-SH/Lys), aiming to effectively treat corneal neovascularization (CNV) by specifically inhibiting the expression of VEGF-A.
methodsThe particle size, zeta potential and stability of the V-SH/Lys nanoparticles loaded with si-VEGF-A were tested. The effects of V-SH/Lys nanoparticles on the tube formation and migration of vascular endothelial cells were evaluated through Transwell, cell scratch assay and cell tube formation assay. A rat model of CNV was established, and the extent of the neovascularization was quantified. The levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in the cornea were also measured. The safety of V-SH/Lys nanoparticles was evaluated through cytotoxicity tests on corneal epithelial cells and pathological examinations of rat fundus tissues.
resultsThe V-SH/Lys nanoparticles exhibited a particle size of 204.5 ± 38.3 nm, a zeta potential of +17.90 ± 6.46 mV, and demonstrated good stability as shown by high performance liquid chromatography (HPLC). In vitro experiments demonstrated that V-SH/Lys could block formation of the tubular structures and migration of vascular endothelial cells. In the CNV model induced by corneal alkali burn in rats, the area of new blood vessels in the V-SH/Lys group was smaller than that in the control group (P<0.01), and the levels of corneal inflammatory factors (TNF-α, IL-6) were significantly reduced. Moreover, V-SH/Lys nanogel exhibited no obvious toxicity to corneal epithelial cells, and no abnormalities were observed in the rat fundus tissues, indicating its favorable safety profile.
conclusionThis study has confirmed that V-SH/Lys nanoparticles, by targeting and regulating VEGF-A, provide an efficient, safe and non-invasive treatment strategy for CNV, and have potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.